Global Organ-On-Chip Market - 2022-2029

Global Organ-On-Chip Market - 2022-2029

Market Overview

The global organ-on-chip market was valued at US$ 150.29 million in 2021 and is estimated to reach US$ 1,427.41 million by 2029, growing at a CAGR of 28.58% during the forecast period (2022-2029).

Organ-on-chip is a multi-channel 3-D microfluid cell culture ship that stimulates activities, mechanisms, and physiological responses of entire organs.

These microdevices are translucent; they provide a window to watch the inner workings of human organs. This technology is being used to develop a whole pipeline of human organs on chips such as lung, gut, liver, heart, skin, bone marrow, pancreas, kidney, and even a system that mimics the blood-brain barrier.

Market Dynamics

The provision of research funds grants is considered the key driver for the progress in the development of OOC devices; the increasing research and development expenditure and growth in the vaccine and drug developments are expected to drive market growth.

The increasing technological advancements and demand for organ-on-chip devices drive market growth.

The global market for organ-on-chips is primarily driven by the surge in demand for organ-on-chip devices in the healthcare industry and the rising number of clinical trials along with the many advantages it helps in successful clinical development, helps pharmaceutical companies in replacing animal cells, comparing studies between humans and animals, study the toxicity of drugs and cosmetics, develop vaccines and drugs to counter bioterrorism threats, etc.

Various latest technological advancements are taking place, and the number of vaccine and drug developments are increasing; hence clinical trials are also increasing. For instance, in Jun 2022, Labcorp, a life science company, announced its latest collaboration with Tigerlily Foundation, an advocacy organization for breast cancer patients. In this collaboration, they will expand the diversity of clinical trials for women of color. Labcorp has also signed the Inclusion pledge for black women of Tigerlily and joined various other life science and healthcare companies.

High costs associated with organ-on-chips devices will hamper the market’s growth.

The high cost of devices will restrain the growth of the organ-on-chip market. This is because of the high manufacturing cost associated with complex manufacturing techniques.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations and operations due to the increase in demand for novel and effective vaccines and drugs and the rise in the number of clinical trials. Various biopharmaceutical companies partnered or collaborated to meet the demands of vaccines with the help of organ-on-chip technology. Various collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in Oct 2020, Emulate and U.S. FDA announced their cooperative research and development agreement allowing various studies in important research areas across FDA offices, including evaluating COVID-19 vaccines and understanding the human immune response.

Segment Analysis

The liver-on-chip model segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The liver-on-chip model segment is the highest market holder in the global organ-on-chip market. The liver-on-chip model share accounted for the largest market because of its animal and in vitro model’s poor efficacy, as the study of toxicity is bounded that delays the drug development processes. According to the WHO report 2022, approx. Two hundred ninety-six million individuals got chronic hepatitis B infection, out of which 820,000 deaths were recorded, with around 1.5 million new cases of infection every year. Preventive vaccines are still accessible post-infection remedy is required. Moreover, around 44,000 individuals suffer from drug-induced liver infections in the United States. Hence the development of novel liver-on-chip devices will have major applications in the various diagnostic and therapeutic fields. It will play a key role in developing new therapeutics for chronic diseases, including liver cirrhosis, hepatitis B and hepatocellular carcinoma. For instance, in Jun 2022, MIMETAS proposed a platform called OrganoPlate Graft for liver and other tissue grafting on the microvascular in vitro grown bed.

Geographical Analysis

North America holds the largest market share of the global organ-on-chip market.

North America dominates the global organ-on-chip (OOC) market, primarily attributed to the increasing number of OOC manufacturing companies and the rising demand for organ-on-chip models. Furthermore, factors including growing expenditure on research and development and the increasing outsourcing of R&D activities. are likely to enhance the growth of the region's Organ-On-Chip market.

Moreover, the growing number of regional clinical trials is responsible for the market’s growth. For instance, North America ranks first in the name of clinical trials performed worldwide. Other factors, such as the high spending of GDP on healthcare, stimulate the market’s growth. Many key developments are taking place based in this region. For instance, in Mar 2021, Emulate Inc., in vitro advanced model provider, launched its Colon Intestine-Chip for inflammatory intestinal disease investigations. This colon intestine chip will summarize the functions of human colon cells, provide a better understanding of inflammation mechanisms, and lead to finding effective drug targets.

Competitive Landscape

The Organ-On-Chip market is highly competitive with local and global companies. Key players contributing to the market’s growth are Emulate, Mimetas B.V., Insphero AG, Organovo Holdings, C.N. Bio, BiomimX, Axosim Technologies, Hesperos Inc., Tissuse Gmbh, Nortis Inc. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in Feb 2022, Mimetas and Astellas, together in OrganoPlate, introduced a human renal proximal blood vessel-on-chip model for studying the acute kidney injury that is caused due to renal ischemia or reperfusion injury.

Emulate Inc.:

Overview:

Emulate Inc. is an organ-on-chip technology provider. They provide human-relevant in vitro models to better understand biological mechanisms of health or disease and develop improved drug therapies. These models are called organ-on-chip. It was established in 2013 and is headquartered in Massachusetts, United States.

Product Portfolio:

Liver-Chip: This quad culture liver chip in the dynamic microenvironment incorporates 4 human cell types that support in vivo functionality, gene expression and physiology. It determines the toxicity, safety and efficacy of AAV-based gene therapy transduction.

Key Development: In Sep 2022, Emulate Inc., in vitro model provider, announced its novel application of adeno-associated virus transduction for a Liver chip that helps researchers test the safety and efficacy of adeno-associated virus vectors in a model of the liver that is relevant to human with results in few weeks. This helps researchers to optimize gene therapy deliveries quickly and accelerates the development.

The global organ-on-chip market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.